Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and PRRT in Advanced GEP-NET
NCT05870423Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in Gastroenteropancreatic neuroendocrine tumor (GEPNET) (4 arms), sponsored by Erasmus MC. Primary endpoints: Incidence and severity of adverse events according to CTCAE v5.0 at 3 years and Maximum Tolerated Dose at 3 years. Started Jun 2022; status: recruiting.
02
Drugs
olaparib
03
Conditions
Gastroenteropancreatic neuroendocrine tumor (GEPNET)
Beyond the preview
Go deeper on NCT05870423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870423.